Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Decitabina orale più Ivosidenib come prima linea per pazienti adulti con AML anziani/non idonei (DECISIVO)

21 settembre 2026 aggiornato da: PETHEMA Foundation

Studio clinico di Fase II, multicentrico, in aperto, che valuta l'efficacia e la sicurezza della decitabina orale più ivosidenib in pazienti adulti con leucemia mieloide acuta di nuova diagnosi di età superiore a 60 anni e/o non idonei per la chemioterapia di induzione standard

The goal of this clinical trial is to learn if the combination of oral decitabine plus ivosidenib works to treat naïve adult patients with acute myeloid leukemia (AML) with IDH1 R132 mutation older than 60 years old or those who are older than 18 years old with defined comorbidities that make them not suitable for standard induction therapy. The main objectives of this clinical trial are:

  • Asses the Complete Remission (CR) and Complete Remission with incomplete marrow recovery (CRi) rates of this treatment.
  • Determine the incidence and severity of all adverse events (AEs).

All participants will receive oral ivosidenib and oral decitabine in treatment cycles of 28 days until disease progression, lack of clinical benefit or the end of the study. Patients who achieve CR/CRi will be elegible to receive allogeneic stem cell transplantation.

Panoramica dello studio

Descrizione dettagliata

A total of 50 participants will be assigned to the single treatment arm which will have treatment cycles of 28 days with Ivosidenib 500 mg/orally on Days 1-28 plus oral decitabine-cedazuridine (one tablet once daily containing 35 mg decitabine and 100 mg cedazuridine as a fixed-dose combination) on days 1-5.

Hydroxiurea or maximum 1 gram/sqm of cytarabine is allowed to control hyperleukocytosis during the screening period as well as during the first two cycles of induction.

Participants will continue their study treatment until documented disease progression per Investigator assessment, unacceptable toxicity, withdrawal of consent, the subject meets other protocol criteria for discontinuation or study completion (whichever occurs first).

Participants who are considered eligible for an allogeneic stem cell transplant after achieving CR/CRi will perform a pre-transplant visit into the study, collecting MRD stats and characteristics of transplant. They will be allowed to resume ivosidenib after day +60 of transplant. The post-transplant schedule can be administered for up to 2 years. If they do not resume ivosidenib they will perform end of trial visit (and if this is not possible the pre-transplant visit will be considered as en of trial visit).

Tipo di studio

Interventistico

Iscrizione (Stimato)

50

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Aveiro, Portogallo
        • Non ancora reclutamento
        • ULS Região de Aveiro
        • Contatto:
          • Cátia Sol dos Reis
      • Funchal, Portogallo
        • Non ancora reclutamento
        • Hospital Central do Funchal
        • Contatto:
          • Rebeca Brito
      • Lisbon, Portogallo
        • Non ancora reclutamento
        • Hospital Santa Maria
        • Contatto:
          • Joana Brioso
      • Lisbon, Portogallo
        • Non ancora reclutamento
        • ULS São José
        • Contatto:
          • Luís Monteiro
      • Porto, Portogallo
        • Non ancora reclutamento
        • Hospital Pedro Hispano
        • Contatto:
          • Ilídia Moreira
      • Albacete, Spagna, 02006
        • Non ancora reclutamento
        • Complejo Hospitalario de Albacete
        • Investigatore principale:
          • Jesús Lorenzo Algarra Algarra
      • Alicante, Spagna
        • Non ancora reclutamento
        • Hospital General Universitario Dr. Balmis
        • Investigatore principale:
          • Carmen Botella, Dr
      • Burgos, Spagna, 09006
        • Reclutamento
        • Hospital Universitario de Burgos
        • Investigatore principale:
          • Jorge Labrador
      • Cáceres, Spagna
        • Reclutamento
        • Hospital San Pedro Alcántara
        • Contatto:
          • Juan Bergua
      • Córdoba, Spagna, 14004
        • Reclutamento
        • Complejo Hospitalario Regional Reina Sofía
        • Investigatore principale:
          • Josefina Serrano López
      • Las Palmas, Spagna
        • Non ancora reclutamento
        • Hospital Universitario de Gran Canaria Doctor Negrín
        • Contatto:
          • Carlos Rodríguez
      • Las Palmas de Gran Canaria, Spagna
        • Non ancora reclutamento
        • Hospital Universitario de Canarias
        • Investigatore principale:
          • Carolina Lacalzada
      • Lugo, Spagna
        • Non ancora reclutamento
        • Hospital Universitario Lucus Augusti
        • Investigatore principale:
          • Aitor Abuín, Dr
      • Madrid, Spagna
        • Non ancora reclutamento
        • H. 12 de Octubre
        • Contatto:
          • Pilar Martínez Sánchez
      • Madrid, Spagna, 28040
        • Non ancora reclutamento
        • Fundación Jiménez Díaz
        • Investigatore principale:
          • José Luis López Lorenzo
      • Madrid, Spagna
        • Non ancora reclutamento
        • Hospital Univeristario Ramón y Cajal
        • Contatto:
          • Pilar Herrera
      • Málaga, Spagna
        • Reclutamento
        • Hospital Virgen de la Victoria
        • Contatto:
          • Maria García Fortes, Dr
      • Seville, Spagna
        • Reclutamento
        • Hospital Universitario Virgen Del Rocío
        • Contatto:
          • Eduardo Rodríguez Arbolí
        • Investigatore principale:
          • Eduardo Rodríguez Arbolí
      • Valencia, Spagna
        • Non ancora reclutamento
        • H. Dr. Peset
        • Contatto:
          • María José Sayas
        • Sub-investigatore:
          • María Pedreño, MD
      • Valencia, Spagna
        • Reclutamento
        • Hospital Universitari i Politècnic La Fe
        • Investigatore principale:
          • Irene Navarro

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Morphological diagnosis of AML (WHO criteria 2022)

  2. Newly diagnosed AML.

  3. IDH1 R132 mutations (centrally assessed by PCR and NGS). A patient will be allowed to be included with local result after approval of the medical monitor.

  4. Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2 if ≥ 60 years of age, or 0 to 3 if ≥ 18 to 60 years.

  5. Age ≥ 18 years with comorbidities contraindicating intensive chemotherapy; or age ≥ 60 years.

    • ≥ 60 years of age;

    • or ≥ 18 to 60 with at least one of the following co-morbidities:

      • ECOG Performance Status of 2 or 3;
      • Cardiac history of CHF requiring treatment or Ejection Fraction ≤ 55% or chronic stable angina;
      • DLCO ≤ 65% or FEV1 ≤ 65% or significant history of chronic pulmonary obstructive;
      • Creatinine clearance ≥ 25 mL/min to < 50 ml/min
      • Moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 × ULN
      • Non active/controlled prior neoplastic disease
      • Any other patient´s comorbidity or disease condition that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the PETHEMA medical monitor before study enrolment (e.g, prior MDS or MPS, high-risk cytogenetics)
  6. Patients <70 years, with favorable risk AML according to ELN will be included only if they are not candidates to standard treatment with intensive chemotherapy.

  7. Adequate renal function as demonstrated by a creatinine clearance ≥ 25 mL/min (calculated by the Cockcroft Gault formula).

  8. Adequate liver function as demonstrated by: aspartate aminotransferase (AST) ≤ 5.0 × ULN, alanine aminotransferase (ALT) ≤ 5.0 × ULN, bilirubin ≤ 2.5 × ULN (unless considered to be due to leukemic disease, in which case it should be approved by the PETHEMA medical monitor).

  9. Subject has a white blood cell count < 30 × 109/L (Hydroxyurea is permitted to meet this criterion)

  10. Female subjects must be either postmenopausal OR permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) OR Women of Childbearing Potential (WOCBP) practicing at least one protocol specified method of birth control. Female subjects of childbearing potential must have negative results for pregnancy tests performed along the study (screening and every three cycles). A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.

  11. Male subjects who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice the protocol specified contraception.

  12. Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.

Exclusion Criteria:

  1. Subject has history of myeloproliferative neoplasm [MPN] with BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
  2. Prior therapy for AML (except hydroxiurea).
  3. Genetic diagnosis of acute promyelocytic leukemia.
  4. Subject is known to be positive for HIV (HIV testing is not required.)
  5. Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. (Hepatitis B or C testing is not required).
  6. Subject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients that in the opinion of the investigator would adversely affect his/her participating in this study.
  7. Any severe uncontrolled systemic infection.
  8. Subject has a history of other malignancies within 1 year prior to study entry which is not controlled and/or requiring active therapy which may compromise the administration of IVO and oral decitabine.
  9. Creatinine clearance <25 mL/min (calculated by the Cockcroft-Gault formula).
  10. Inadequate liver function as demonstrated by AST or ALT > 5.0 × ULN, or bilirubin > 2.5 × ULN (unless considered to be due to leukemic disease, in which case it should be approved by the PETHEMA medical monitor)
  11. Subject has a white blood cell count > 30 × 109/L that is not controlled using hydrea or 1 gr/sqm/day per 1 day of cytarabine.
  12. Contraindications for IVO or oral decitabine according to the SmPC.
  13. Patient has a heart rate-corrected QT interval using Fridericia's method QT for corrected heart rate (QTcF) ≥450 msec or any other factor that increases the risk of QT prolongation or arrhythmic events (e.g., hypokalemia, family history of long QT interval syndrome). Patients with prolonged QTcF interval in the setting of bundle branch block may participate in the trial.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Decitabine+Ivosidenib

Participants will receive treatment cycles of 28 days with Ivosidenib 500 mg/orally on Days 1-28 plus oral decitabine-cedazuridine (one tablet once daily containing 35 mg decitabine and 100 mg cedazuridine as a fixed-dose combination) on days 1-5. Hydroxiurea or maximum 1 gram/sqm of cytarabine is allowed to control hyperleukocytosis during the screening period as well as during the first two cycles of induction.

Participants who achieve CR/CRi can be submitted to allogeneic stem cell transplant and will be allowed to resume ivosidenib after day +60 of transplant. The post-transplant schedule can be administered for up to 2 years.

Oral Decitabine (Decitabine/Cedazuridine 35 Mg-100 Mg) will be administerd on Days 1-5 of each treatment cycle

Ivosidenib 500 mg/orally on Days 1-28 of each treatment cycle

0.5-6 gram/day orally during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis

Maximum 1 gram/sqm/day during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis

Only for those participants achieving CR/CRi

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Rate of CR/CRi
Lasso di tempo: 3 years

To assess the rates of Complete Remission (CR) and Complete Remission with incomplete marrow recovery (CRi) of participants treated with Ivosidenib plus Decitabine

3 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Rate CR/CRi compared to historical cohort
Lasso di tempo: 3 years

To evaluate the CR (Complete Remission)/CRi (Complete Remission with incomplete marrow recovery) rates after 2, 3 and 6 cycles of Ivosidenib and oral Decitabine, and compare with a matched historical cohort.

3 years
OS compared to historical cohort
Lasso di tempo: 3 years

To assess OS (overall survival, measured as the number of days from the date of enrollment to the date of death, whatever the cause of death) and compare the median between Ivosidenib with oral Decitabine and a matched historical cohort.

3 years
EFS compared to historical cohort
Lasso di tempo: 3 years

To evaluate EFS (event-free survival, defined as the number of days from enrollment until the date of progressive disease, relapse from CR or CRi, failure to achieve CR or CRi, or death from any cause) and compare with a matched historical control cohort

3 years
Hematologic and non-hematologic toxicity and AE
Lasso di tempo: 3 years

Toxicity and adverse events (AE) will be recorded and evaluated to determine treatment safety. Toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.019.

3 years
Quality of CR
Lasso di tempo: 3 years

The quality of the Complete Remission (CR) will measured by the study of minimal residual disease percentages in the bone marrow using multiparametric flow cytometry and Next Generation Sequencing

3 years
Early mortality
Lasso di tempo: 3 years

To evaluate the mortality rate during the first 60 days of treatment

3 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Cattedra di studio: Pau Montesinos, Hospital Universitari i Politèncic La Fe

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

12 giugno 2026

Completamento primario (Stimato)

1 aprile 2029

Completamento dello studio (Stimato)

1 aprile 2029

Date di iscrizione allo studio

Primo inviato

27 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

27 marzo 2026

Primo Inserito (Effettivo)

2 aprile 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

21 settembre 2026

Ultimo verificato

1 marzo 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi